The OncoMasTR gene expression profiling test for early-stage breast cancer prognosis was first discovered via a novel transcriptional network analysis approach, which identified upstream Master Transcriptional Regulators (MTRs) of three independent breast cancer prognosis signatures1,2. The test has been analytically and clinically validated for use as a decentralised kit and the signature was shown to be significantly prognostic for distant recurrence for ER-positive, HER2-negative early stage breast cancer with up to three involved lymph nodes3.

OncoMark is an Irish-based diagnostic company focused on the development of novel panels of cancer biomarkers to aid treatment decisions and allow more tailored patient management, ultimately improving the quality of life for cancer patients.

Tel: +353 (1) 716 3666
OncoMark Ltd, NovaUCD, Belfield, Dublin 4, Ireland

1 Lanigan F. et al. FEBS J 2015; 282:3455-3473
2 Moran B. et al. Cancer Res 2017; 77(9): 2186-2190
3 Sestak I. et al. J Clin Oncol 2018, 36 (suppl; abstr 553)
Supported browsers
Chrome Windows 7 Pro and Windows 10 Pro
Firefox Windows 7 Pro and Windows 10 Pro
Internet Explorer 11 (Windows 7 Pro)
OncoMark Ltd. is registered in Ireland under No. 440369